Mirum Pharmaceuticals, Inc.
MIRM
Pozycja w akcjach
#3313
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to... Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Cena akcji
$81.34
Kapitalizacja rynkowa
$5.28B
Zmiana (1 dzień)
1.49%
Zmiana (1 rok)
10.61%
Kraj
US
Handel Mirum Pharmaceuticals, Inc. (MIRM)
Kategoria
Healthcare
EPS dla Mirum Pharmaceuticals, Inc. (MIRM)
EPS na dzień June 2026 TTM: $-14.56
Według najnowszych raportów finansowych i ceny akcji firmy Mirum Pharmaceuticals, Inc., obecny EPS (TTM) wynosi $-14.56. Na koniec roku 2023 firma miała EPS w wysokości $-4.00, spadek w porównaniu do do EPS z roku 2022, który wynosił $-4.01.
Historia EPS dla Mirum Pharmaceuticals, Inc. od 2018 do 2026
EPS na koniec każdego roku
| Rok | EPS | Zmień |
|---|---|---|
| 2026 (TTM) | $-14.56 | 687.03% |
| 2024 | $-1.85 | -53.75% |
| 2023 | $-4.00 | -0.25% |
| 2022 | $-4.01 | 44.77% |
| 2021 | $-2.77 | -32.27% |
| 2020 | $-4.09 | 78.60% |
| 2019 | $-2.29 | 205.33% |
| 2018 | $-0.75 | 0.00% |
EPS dla podobnych firm lub konkurentów
| Firma | EPS | Różnica w EPS | Kraj |
|---|---|---|---|
| $17.32 | -218.96% |
US
|
|
| $-7.98 | -45.19% |
US
|
|
| $-5.29 | -63.67% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -290.52% |
NL
|
